Adrenal androgens, insulin resistance, and cardiovascular disease

Seminars in Reproductive Endocrinology

Volumn 14, Issue 1, 1996, Pages 29-34

  Casson, Peter R ^a,b   Hornsby, Peter J ^a,b   Buster, John E ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Division of Endocrinology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; INSULIN; PRASTERONE; PRASTERONE SULFATE;

ANDROGEN BLOOD LEVEL; CARDIOVASCULAR DISEASE; HEART PROTECTION; HYPERANDROGENISM; HYPERINSULINEMIA; INSULIN RESISTANCE; PRIORITY JOURNAL; REVIEW;

EID: 0030010398     PISSN: 07348630     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1016306     Document Type: Review

References (54)

1. Levy RI: Prevalence and epidemiology of cardiovascular disease. In JB Wyngaarden, L Smith (eds): Cecil Textbook of Medicine. Philadelphia, WB Saunders Co, 1985, p 155
2. Stern MP, Haffner SM: Body fat distribution and hyperinsulinemia as risk factors for diabetes and cardiovascular disease. Arteriosclerosis 6:123-130, 1986
3. Stern MP: Diabetes and cardiovascular disease. Diabetes 44:369-374, 1995
4. Orentreich N, Brind JL, Rizer RL, Vogelman JH: Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab 59:551-555, 1984
5. Sapolsky RM, Vogelman JH, Orentreich N, Altmann J: Senescent decline in serum dehydroepiandrosterone sulfate concentrations in a population of wild baboons. J Gerontol 48:B196-B200, 1993
6. Casson PR, Buster JE: DHEA administration to humans: Panacea or palaver? Semin Reprod Endocrinol 13:247-256, 1995
7. 4-androstenedione and dehydroepiandrosterone sulfate during oral glucose tolerance test in normal females. J Clin Endocrinol Metab 73:781-784, 1991
8. Nestler JE, Clore JN, Strauss JF III, Blackard WG: The effects of hyperinsulinemia on serum testosterone, progesterone, dehydroepiandrosterone sulfate and cortisol levels in normal women and in a woman with hyperandrogenism, insulin resistance and acanthosis nigricans. J Clin Endocrinol Metab 64:180-184, 1987
9. Schriock ED, Buffington CK, Givens JR, Buster JE: Enhanced post-receptor insulin effects on women following dehydroepiandrosterone infusion. J Soc Gynecol Invest 1:74-78, 1994
10. Buffington CK, Pourmotabbed G, Kitabchi AE: Case report: Amelioration of insulin resistance in diabetes with dehydroepiandrosterone. Am J Med Sci 306:320-324, 1993
11. Casson PR, Faquin LC, Stentz FB, et al: Replacement of dehydroepiandrosterone enhances T-lymphocyte insulin binding in postmenopausal women. Fertil Steril 63:1027-1031, 1995
12. Nestler JE, Barlascini CO, Clore JN, Blackard WG: Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men. J Clin Endocrinol Metab 66:57-61, 1988
13. Gordon GB, Bush DE, Weisman HF: Reduction of atherosclerosis by administration of dehydroepiandrosterone. J Clin Invest 82:712-720, 1988
14. Arad Y, Badimon JO, Hembrec W, Ginsberg HN: Dehydroepiandrosterone feeding prevent aortic fatty streak formation and cholesterol accumulation in cholesterol-fed rabbit. Arteriosclerosis 9:159-166, 1989
15. Poretsky L: On the paradox of insulin-induced hyperandrogenism in insulin-resistant states. Endocrinol Rev 12:3-12, 1991
16. Friedl KE, Jones RE, Hannan CJ, Plymate SR: The administration of pharmacological doses of testosterone or 19-nortestosterone to normal men is not associated with increased insulin secretion or impaired glucose tolerance. J Clin Endocrinol Metab 68:971, 1989
17. Geffner ME, Kaplan SA, Bersch N, Golde DW, Landaw EM, Chang RZ: Persistence of insulin resistance in polycystic ovarian disease after inhibition of ovarian steroid secretion. Fertil Steril 45:327-333, 1986
18. Nestler JE, Usiskin KS, Barlascini CO, Welty DF, Clore JN, Blackard WG: Suppression of serum dehydroepiandrosterone sulfate levels by insulin: An evaluation of possible mechanisms. J Clin Endocrinol Metab 69:1040-1046, 1989
19. Nestler JE, Beer NA, Jakubowicz DJ, Beer RM: Effects of a reduction in circulating insulin by metformin on serum dehydroepiandrosterone sulfate in nondiabetic men. J Clin Endocrinol Metab 78:549-554, 1994
20. Beer NA, Jakubowicz DJ, Beer RM, Arocha IR, Nestler JE: Effects of nitrendipine on glucose tolerance and serum insulin and dehydroepiandrosterone sulfate levels in insulin-resistant obese and hypertensive men. J Clin Endocrinol Metab 76:178-183, 1993
21. Nestler JE, McClanahan MA, Clore JN, Blackard WG: Insulin inhibits adrenal 17,20-lyase activity in man. J Clin Endocrinol Metab 74:362-367, 1992
22. Nestler JE, Kahwash Z: Sex-specific action of insulin to acutely increase the metabolic clearance rate of dehydroepiandrosterone in humans. J Clin Invest 94:1484-1489, 1994
23. Lavallée B, Provost PR, Kahwash Z, Nestler JE, Bélanger A: Effect of insulin on plasma levels of DHEA metabolites in men. DHEA and Aging Conference, Washington, DC, 1995, Abstract P12
24. Kristiansen SB, Endoh A, Casson PR, Buster JE, Hornsby PJ: Induction of steroidogenic enzyme genes by insulin and IGF-I in cultured adult human adrenocortical cells and effects on adrenal androgen biosynthesis. J Clin Endocrinol Metab 1995 (submitted)
25. Hornsby PJ: Biosynthesis of DHEAS by human adrenal cortex and its age related decline. Ann NY Acad Sci 774:29-46, 1995
26. vy/ A mice by dehydroepiandrosterone. Lipids 12:409-413, 1977
27. Coleman DL, Leiter EH, Schwizer RW: Therapeutic effects of dehydroepiandrosterone (DHEA) in diabetic mice. Diabetes 31:830-833, 1982
28. Schriock ED, Buffington CK, Hubert GD, et al: Divergent correlations of circulating dehydroepiandrosterone sulfate and testosterone with insulin levels and insulin receptor binding. J Clin Endocrinol Metab 66:1329-1331, 1988
29. Mortola J, Yen SSC: The effects of dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women. J Clin Endocrinol Metab 71:696-704, 1990
30. Bates GW, Egerman RS, Umstot ES, Buster JE, Casson PR: Dehydroepiandrosterone attenuates study-induced declines in insulin sensitivity in postmenopausal women. Ann NY Acad Sci 774:291-293, 1995
31. Morales AJ, Nokn JJ, Nelson JC, Yen SSC: Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 78:1360-1367, 1994
32. Eich DM, Nestler JE, Johnson DE, et al: Inhibition of accelerated coronary atherosclerosis with dehydroepiandrosterone in the heterotopic rabbit model of cardiac transplantation. Circulation 87:261-269, 1993
33. Aldercreutz H, Kerstell J, Schaumann KO, Svanborg A, Vihko R: Plasma lipids and steroid hormones in patients with hypercholesterolemia or hyperlipemia during dehydroepiandrosterone sulphate administration. Eur J Clin Invest 2:91-95, 1972
34. Saenger P, New M: Inhibitory action of dehydroepiandrosterone (DHEA) on fibroblast growth. Experientia 33:966-967, 1976
35. Lopez-S A, Krehl WA: In vivo effect of dehydroepiandrosterone on red blood cells glucose-6-phosphate dehydrogenase. Proc Soc Exp Med 126:776-778, 1967
36. Jesse RL, Loesser K, Eich DM, et al; Dehydroepiandrosterone inhibits human platelet aggregation in vitro and in vivo. Ann NY Acad Sci 774:281-290, 1995
37. Beer NA, Jakubowicz DJ, Matt DE, Beer RM, Nestler JE: Oral dehydroepiandrosterone (DHEA) administration produces plasma levels of plasminogen activator antigen (t-PA) in men. DHEA and Aging Conference, Washington, DC, 1995, Abstract P9
38. Mitchell LE, Sprecher DL, Borecki IB, Rice T, Laskarzewski PM, Rao DC: Evidence for an association between dehydroepiandrosterone sulfate and nonfatal premature myocardial infarction in males. Circulation 89:89-93, 1995
39. Slowinska-Srzednicka J, Zgliczyński S, Ciświcka-Sznajderman M, et al: Decreased plasma dehydroepiandrosterone sulfate and dihydrotestosterone concentrations in young men after myocardial infarction. Atherosclerosis 79:197-203, 1989
40. Herrington DM, Gordon GB, Achuff SC, et al: Plasma dehydroepiandrosterone and dehydroepiandrosterone sulfate in patients undergoing diagnostic coronary angiography. J Am Coll Cardiol 16:862-870, 1990
41. Herrington DM: DHEA and coronary atherosclerosis. Ann NY Acad Sci 774:271-280, 1995
42. Zumoff B, Troxler RG, O'Connor J, et al: Abnormal hormone levels in men with coronary artery disease. Arteriosclerosis 2:58-67, 1982
43. Contoreggi CS, Blackman MR, Andres R, et al: Plasma levels of estradiol, testosterone, and DHEAS do not predict risk of coronary artery disease in men. J Androl 11:460-470, 1990
44. Rice T, Sprecher DL, Borecki IB, Mitchell LE, Laskarzewski PM, Rao DC: The Cincinnati myocardial infarction and hormone family study: Family resemblance for dehydroepiandrosterone sulfate in control and myocardial infarction families. Metabolism 42:1284-1290, 1993
45. Newcomer LM, Manson JE, Barbieri RL, Hennekens CH, Stampfer MJ: Dehydroepiandrosterone sulfate and the risk of myocardial infarction in US male physicians: A prospective study. Am J Epidemiol 140:870-877, 1994
46. Barrett-Connor E, Khaw KT, Yen SSC: A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. N Engl J Med 315:1519-1524, 1986
47. Barrett-Connor E, Khaw KT: Absence of inverse relation of dehydroepiandrosterone sulfate with cardiovascular mortality in postmenopausal women. N Engl J Med 317:711, 1995
48. Barrett-Connor E, Goodman-Gruen D: Dehydroepiandrosterone sulfate does not predict cardiovascular death in post-menopausal women. Circulation 91:1757-1760, 1995
49. Barrett-Connor E, Goodman-Gruen D: The epidemiology of DHEAS and cardiovascular disease. Ann NY Acad Sci 774:259-270, 1995
50. Khaw KT, Tazuke S, Barrett-Connor E: Cigarette smoking and levels of adrenal androgens in postmenopausal women. N Engl J Med 318:1705-1709, 1988
51. Tazuke S, Khaw KT, Barrett-Connor E: Exogenous estrogen and endogenous sex hormones. Medicine 71:44-50, 1992
52. Field AE, Colditz GA, Willett WC, Longcope C, McKinlay JB: The relation of smoking, age, relative weight, and dietary intake to serum adrenal steroids, sex hormones, and sex hormone-binding globulin in middle-aged men. J Clin Endocrinol Metab 79:1310-1316, 1994
53. Rotter JI, Wong L, Lifrak ET, Parker LN: A genetic component to the variation of dehydroepiandrosterone sulfate. Metabolism 34:731-736, 1985
54. Orentreich N, Brind JL, Vogelman JH, Andres R, Baldwin H: Long-term longitudinal measurements of plasma dehydroepiandrosterone sulfate in normal men. J Clin Endocrinol Metab 75:1002-1004, 1992